Overview

Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
0
Participant gender:
All
Summary
This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy procedures.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hartford Hospital
Treatments:
Bupivacaine
Dexamethasone
Epinephrine
Criteria
Inclusion Criteria:

- Patients scheduled for elective laparoscopic colectomy surgery to be performed by one
of the 4 colorectal surgeons in the study.

- English speaking patients

- Patients with American Society of Anesthesiology (ASA) physical status score I- IV

Exclusion Criteria:

1. Emergency laparoscopic colectomy surgery

2. Patients with distant metastatic cancers (e.g. bone, lung, brain).

3. Scheduled for multi organs resection surgery in addition to colectomy.

4. Patients with contraindications to TAP or RS blocks including but not limited to
anatomical abnormality, previous surgical intervention that limits or prevents
receiving bilateral TAP blocks (e.g. surgical mesh at the site of TAP or RS block), or
infection at the injection site.

5. Current colostomies.

6. History of allergy to local anesthetics.

7. Coagulopathy or coagulation disorder. Also patients who are receiving antithrombotic
medications as a contraindication to receiving single shot peripheral nerve blockade
as per the most recent American Society of Regional Anesthesiology (ASRA)
guidelines.16

8. Weight < 40 kg, as 40 mL of Bupivacaine 0.25%, or combination of 20 mL of bupivacaine
0.25% with 20 mL of liposomal bupivacaine is greater than the maximal dose allowed,
given concern for local anesthetic toxicity.

9. Patients who take long acting opioid medication, or on continuous opioid > 50 MME per
day for at least 30 days within 90 days prior to surgery. Also patients who have
chronic pain syndrome with a recent preoperative consultation to the chronic pain
service.

10. Patients with current substance abuse, or history of substance abuse within 3 months,
this includes any illicit drugs or excessive alcohol consumption as defined 4 or more
drinks per day or 8 or more drinks per week for women and 5 or more drinks per day or
15 or more drinks per week for men.15

11. Pregnant, nursing, or planning to become pregnant during the study or within 1 month
postoperatively

12. Refusal or lack of providing the study consent